Trading of Alumis was halted at 09:32 AM EST due to "LULD pause". Alumis (ALMS) Competitors $4.78 -0.10 (-2.05%) Closing price 04:00 PM EasternExtended Trading$4.76 -0.02 (-0.31%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. MLYS, PAHC, COLL, WVE, RCUS, SYRE, ARDX, PHVS, AVDL, and NTLAShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Wave Life Sciences (WVE), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Ardelyx (ARDX), Pharvaris (PHVS), Avadel Pharmaceuticals (AVDL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Mineralys Therapeutics Phibro Animal Health Collegium Pharmaceutical Wave Life Sciences Arcus Biosciences Spyre Therapeutics Ardelyx Pharvaris Avadel Pharmaceuticals Intellia Therapeutics Alumis (NASDAQ:ALMS) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Does the media prefer ALMS or MLYS? In the previous week, Mineralys Therapeutics had 4 more articles in the media than Alumis. MarketBeat recorded 17 mentions for Mineralys Therapeutics and 13 mentions for Alumis. Mineralys Therapeutics' average media sentiment score of 0.83 beat Alumis' score of -0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, ALMS or MLYS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/AN/AN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.28 Do insiders & institutionals believe in ALMS or MLYS? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ALMS or MLYS more profitable? Alumis' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Mineralys Therapeutics N/A -67.97%-62.40% Do analysts recommend ALMS or MLYS? Alumis presently has a consensus target price of $24.86, indicating a potential upside of 443.33%. Mineralys Therapeutics has a consensus target price of $38.00, indicating a potential upside of 138.02%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ALMS or MLYS? Alumis received 3 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Alumis an outperform vote while only 95.24% of users gave Mineralys Therapeutics an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes23100.00% Underperform VotesNo VotesMineralys TherapeuticsOutperform Votes2095.24% Underperform Votes14.76% SummaryAlumis beats Mineralys Therapeutics on 8 of the 12 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$215.80M$6.55B$5.40B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A9.1626.7419.97Price / SalesN/A258.53394.93122.22Price / CashN/A65.8538.2534.62Price / BookN/A6.546.874.59Net IncomeN/A$143.98M$3.23B$248.18M7 Day Performance1.44%4.65%5.01%2.15%1 Month Performance-2.66%9.18%12.82%16.14%1 Year PerformanceN/A-1.33%17.63%8.06% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.2013 of 5 stars$4.78-2.0%$24.86+420.0%N/A$225.72MN/A0.00N/AEarnings ReportTrading HaltedHigh Trading VolumeMLYSMineralys Therapeutics2.7745 of 5 stars$15.36+0.0%$33.00+114.8%+25.7%$998.18MN/A-4.2328PAHCPhibro Animal Health3.5291 of 5 stars$24.03+0.8%$20.00-16.8%+32.1%$971.63M$1.11B49.981,860Positive NewsCOLLCollegium Pharmaceutical4.0712 of 5 stars$30.12+2.7%$43.80+45.4%-12.3%$965.57M$664.28M12.95210News CoveragePositive NewsWVEWave Life Sciences4.4076 of 5 stars$6.27-0.6%$21.17+237.9%+2.5%$965.37M$108.30M-5.64240Positive NewsGap DownRCUSArcus Biosciences3.5699 of 5 stars$8.66+1.1%$25.67+196.4%-47.4%$919.61M$141M-2.76500Positive NewsGap DownSYRESpyre Therapeutics2.3372 of 5 stars$15.15+4.2%$53.40+252.5%-58.2%$914.09M$890,000.00-2.03100Positive NewsGap DownARDXArdelyx4.5248 of 5 stars$3.85+13.8%$10.39+170.2%-47.3%$912.76M$361.71M-23.8490Insider TradePHVSPharvaris1.2909 of 5 stars$16.45+3.4%$40.67+147.3%-16.5%$859.91MN/A-5.8730AVDLAvadel Pharmaceuticals2.2178 of 5 stars$8.86-0.4%$19.43+119.4%-40.3%$854.68M$169.12M-11.2070NTLAIntellia Therapeutics4.6481 of 5 stars$8.21+1.5%$36.90+349.7%-62.6%$851.66M$45.57M-1.51600Analyst Forecast Related Companies and Tools Related Companies MLYS Alternatives PAHC Alternatives COLL Alternatives WVE Alternatives RCUS Alternatives SYRE Alternatives ARDX Alternatives PHVS Alternatives AVDL Alternatives NTLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALMS Stock Free ALMS Stock Alerts